Effect of Benralizumab on Airway Remodeling in Asthma

Asthma Clinical Trial

— BENRAMOD  

Official title:

Effect of Benralizumab on Airway Remodeling in Asthma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04365205
• Other study ID #: CHUBX 2019/34
• Status: Recruiting
• Start date: September 23, 2020
• Est. completion date: October 5, 2024

Study information

• Verified date: February 2024
• Source: University Hospital, Bordeaux
• Contact: Pierre-Olivier GIRODET, MD, PhD
• Phone: +33 5 57 62 31 94
• Email: pierre-olivier.girodet[@]u-bordeaux.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The anti-interleukin (IL)-5 receptor benralizumab inhibits eosinophilic inflammation but its potential effect on airway remodeling remains unknown. The main objective of this study is to assess the effect of benralizumab in an in vitro model of airway remodeling using cells obtained from asthmatic patients.

Description:

Sixty subjects will be recruited: 20 patients with severe asthma patients, 20 patients with non-severe asthma and 20 non-asthmatic controls. Inclusion visit will include written informed consent, asthma questionnaire, clinical examination, lung function testing, prick tests and assessment of airway remodeling using CT scan and MRI. Bronchial specimens from all subjects will be obtained by fiberoptic bronchoscopy. Airway remodeling will be evaluated by morphological analysis. After BSM cell culture, BSM cells function will be assessed in vitro in the absence or presence of benralizumab using proliferation (BrdU) and chemotactism experiments, ELISA, RT-PCR (polymerase chain reaction ) and electronic microscopy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: October 5, 2024
• Est. primary completion date: October 5, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Healthy subjects

• Written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
• Age higher than 18 years.
• No prior history of any chronic respiratory disease including asthma.
• No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema.
• No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit 1.
• Normal lung function with FEV1 > 90%. Non-severe asthmatics subjects
• • Written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
• Age higher than 18 years.
• Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA), i.e. GINA steps 1, 2 or 3 (18).
• Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in FEV1 within 12 months before enrolment, or PC20 methacholine < 16 mg/mL documented within 12 months prior to screening.
• Documented blood eosinophils =300 cells per µL within 12 months or blood eosinophils =150 cells per µL at visit 1. Severe asthmatics subjects
• • Written inform consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
• Age higher than 18 years.
• Diagnosis of severe asthma according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) task force (19).
• Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in FEV1 within 12 months before enrolment.
• Documented blood eosinophils =300 cells per µL within 12 months or blood eosinophils =150 cells per µL at visit 1.

Exclusion Criteria:

• Active smoker or former smoker.
• Diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
• CT scan abnormality related to any respiratory disease other than asthma.
• Recent asthma exacerbation (less than 6 weeks before bronchoscopy).
• Contraindications related to bronchoscopy:
• coagulation disorders,
• unstable cardiovascular conditions,
• FEV1 lower than 1 litter,
• a fasting state of less than 6 hours for food and less than 2 hours for drink.
• Contraindications to general anesthesia or medications (for propofol: hypersensitivity to the active substance and to any of the excipients; for lidocaine: hypersensitivity to the active substance and to any of the excipients or to local anesthetics of the amide type, epilepsy, porphyria) used in the bronchoscopy procedure.
• Contraindications related to MRI:
• Pacemaker or implantable cardioverter defibrillator
• Metallic foreign body in the eye
• Cerebral aneurysm clips
• Insulin pumps
• Claustrophobia
• Positive urinary pregnancy test at screening for women of child-bearing potential
• Breastfeeding woman.
• Previously received benralizumab.
• History of any clinically significant medical illness or medical disorders including (but not limited to) cardiovascular disease, neuromuscular, hematological disease including bleeding disorders, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.
• Recent history (within previous 6 months) of alcohol or drug abuse.
• Persons placed under judicial protection.
• Persons participating in another research including a period of exclusion still in course.
• Severely altered physical and/or psychological health which, according to, the investigator, could affect the participant's compliance of the study.

Related Conditions & MeSH terms

• Airway Remodeling
• Asthma

Intervention

Procedure:
• Endobronchial biopsy
Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 µg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.

Locations

Country	Name	City	State
France	CIC-P - Centre François Magendie - G3 - Hôpital Haut-Lévêque	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Bronchial smooth muscle (BSM) cells obtained from severe asthmatics measured in vitro using BrdU incorporation.	Determine the proliferation of BSM cells obtained from severe asthmatics measured in vitro using BrdU incorporation.	Month 12
Secondary	Number of cultured BSM cell from non-severe asthmatics and healthy volunteers measured using BrdU incorporation.	Determine the proliferation of cultured BSM cell from non-severe asthmatics and healthy volunteers measured using BrdU incorporation.	Month 12
Secondary	Number of different genes	Gene expression within BSM cells (RT-PCR, nCCounter Immunology panels)	Month 12
Secondary	Measure the inflammatory mediators and extracellular components	Production of inflammatory mediators and extracellular components by cultures BSM cells (ELISA, bio-Plex® Multiples Immunoassays)	Month 12
Secondary	Measure the fluorescence intensity of IL-5 receptor subunit alpha on BSM cells	Determine of expression of IL-5 receptor subunit alpha on BSM cells (% of positive cells, mean fluorescence intensity) using flow cytometry	Month 12
Secondary	Count the number of mitochondria / BSM area (x107/mm2)	Determine of number of mitochondria / BSM area (x107/mm2) and mitochondrial density using electron microscopy	Month 12
Secondary	Count the number of eosinophils/smooth muscle area using optic microscopy	Histological criteria: BSM area (% of tissue area), number of eosinophils/smooth muscle area using optic microscopy	Month 12
Secondary	Measure the bronchial dimension by CT-scan	Bronchial dimensions assessed by CT-scan	Month 12
Secondary	Measure the bronchial dimension by MRI	Bronchial dimensions assessed by MRI	Month 12
Secondary	Measure the lung low single intensity and low attenuation values using MRI	Determine the Lung low single intensity and low attenuation values using MRI	Month 12
Secondary	Measure the lung low single intensity and low attenuation values using CT-scan	Determine the Lung low single intensity and low attenuation values using CT-scan	Month 12